GLP-1/glucagon dual-agonist peptide · Fact sheet
Mazdutide
Also known as IBI362 · LY3305677
Mazdutide is a GLP-1/glucagon dual agonist approved in China for defined weight-management use and studied in randomized metabolic trials. Chinese approval does not confer FDA approval or establish equivalence of research products.
What is Mazdutide?
It activates GLP-1 and glucagon receptors, unlike tirzepatide, which combines GLP-1 and GIP activity.
The exact product, indication and country determine approval; a receptor combination alone does not determine clinical performance.
Benefits & claims
Interest centers on weight and metabolic disease, including whether glucagon-related activity changes liver and energy outcomes.
What the evidence supports
- At week 32 in GLORY-1, mean weight change was about −10.1% and −12.6% in the 4 and 6 mg groups, versus +0.45% with placebo.
- The trial is direct human evidence for its studied population, not a comparison proving superiority to every other incretin medicine.
- Weight change does not itself establish reduced cardiovascular events or long-term safety.
Research areas
- Weight management in Chinese adults
- Type 2 diabetes research
Dosage & frequency
Human study contextGLORY-1 provides a trial reference; this summary does not reproduce Chinese prescribing information.
GLORY-1 (NCT05607680)
Chinese adults aged 18–75 with BMI at least 28, or 24 to below 28 plus a weight-related condition
- Amount
- Assigned target doses of 4 or 6 mg in separate groups
- Frequency
- Once weekly within a 48-week trial; co-primary evaluation at week 32
- Route studied or labeled
- Subcutaneous study treatment
Target doses followed trial escalation; the full escalation, adjustment and eligibility rules are omitted. This is trial context rather than a complete approved-label schedule.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- It activates GLP-1 and glucagon receptors, unlike tirzepatide, which combines GLP-1 and GIP activity.
Formulation differences
- The exact product, indication and country determine approval; a receptor combination alone does not determine clinical performance.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Long-term cardiovascular and other clinical outcomes
- Generalizability across populations
- Exact formulation and risk differences outside the approved Chinese product
Side effects & risks
- Gastrointestinal adverse effects, including diarrhea and nausea, were common in phase 2 research.
- Trial tolerability cannot establish rare harms, every interaction or equivalence of unverified formulations.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Moderate human evidenceGLORY-1 randomized 610 Chinese adults. Phase 2 and phase 3 studies show meaningful weight reduction, but population, formulation and long-term clinical-outcome limits remain.
Studies
610-person GLORY-1 phase 3 trial.
248-person low-dose phase 2 analysis.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
China has approved mazdutide injection for chronic weight management in adults with obesity or overweight under its local product rules. There is no FDA-approved mazdutide product; the Chinese approval does not apply to unrelated online formulations.
Approved outside the U.S.; not FDA approved
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Long-term cardiovascular and other clinical outcomes
- Generalizability across populations
- Exact formulation and risk differences outside the approved Chinese product
Summary
Weight change does not itself establish reduced cardiovascular events or long-term safety.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- medical institutionSuzhou market regulator: mazdutide NMPA approval
Official local regulator notice documenting NMPA approval for chronic weight management in adults with obesity or overweight.
- pubmedOnce-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
610-person GLORY-1 phase 3 trial.
- pubmedA phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.
248-person low-dose phase 2 analysis.